Feature | June 24, 2014

New Study Develops Cutting-edge Echocardiography Method for Diagnosis of Acute Coronary Syndromes

June 24, 2014 — Researchers have announced the results of a clinical study that used a novel echocardiographic technique to detect and quantify damage to heart muscle even after an episode of mild cardiac injury from ischemia (low blood flow to the heart) has resolved. These findings provide hope for detecting potential heart attack victims before they experience life-threatening symptoms.

“The ability to detect heart damage due to low blood flow that occurs downstream from a coronary blockage is key to the early diagnosis of heart attack or for identifying patients who are at very high risk for heart attack,” said primary investigator Brian H. Mott, M.D. Mott is a cardiology research fellow at Oregon Health and Science University in Portland, Ore.; he and his colleagues used myocardial contrast echocardiography with custom-designed microbubble contrast agents, which can be injected through a simple IV and then bind to injured tissue to detect molecular changes that occurred up to six hours after very brief reduction in blood flow. “An issue is that our clinical tools for diagnosing threatened heart attack are far from perfect,” Mott commented. “Our approach using ‘smart’ targeted microbubbles could allow the clinician to detect problems at the bedside in just minutes. Moreover, the technique works to detect injury long after it has resolved and can be used to help judge patient risk according to the size of the area that is jeopardized by low blood flow.”

Researchers on the study, “Myocardial Contrast Echocardiography Molecular Imaging With Phosphatidylserine-enriched Microbubbles for Detection and Spatial Quantification of Myocardial Ischemia,” included Brian H. Mott, William H. Packwood, Brian P. Davidson and Jonathan R. Lindner from Oregon Health and Science University in Portland, Ore.

For more information: www.asecho.org

Related Content

News | Cardiac Diagnostics| February 17, 2017
Levels of a protein in the blood associated with heart disease are also linked to early-stage brain damage, according...
Mercator MedSystems, DANCE trial data, ISET, LINC, Bullfrog Micro-Infusion Device
News | Peripheral Arterial Disease (PAD)| February 15, 2017
Mercator MedSystems announced that the national co-principal investigators of the company’s DANCE trial each presented...
Medtronic, IDE approval, IN.PACT Admiral drug-coated balloon, DCB, end-stage renal disease
News | Drug-Eluting Balloons| February 08, 2017
Medtronic plc announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug Administration...
CSI, LIBERTY 360 Study, ISET 2017, six-month data, lower extremity PAD
News | Atherectomy Devices| February 08, 2017
February 8, 2017 — Cardiovascular Systems (CSI) presented six-month data from its LIBERTY 360° post-market study in a
GE Healthcare, Rapiscan stress imaging agent, North America, Rapidscan Pharma Solutions Inc.
News | Pharmaceuticals| February 07, 2017
GE Healthcare’s Life Sciences business announced in January that it acquired Rapidscan Pharma Solutions Inc., which has...
Penn Medicine, heart failure causes, YAP and TAZ proteins, Journal of Clinical Investigation study
News | Heart Failure| February 07, 2017
February 7, 2017 — Of the more than 700,000 Americans who suffer a heart attack each year, about a quarter go on to d
Avinger, VISION Study, two-year outcomes, LINC, Lumivascular technology, Pantheris, OCT-guided atherectomy
News | Atherectomy Devices| February 03, 2017
Avinger Inc. recently announced positive two-year clinical data from the pivotal VISION study of the company’s...
stress echo, complex heart conditions, guideline document, ASE, EACVI
News | Stress Test Systems| February 03, 2017
For over 20 years, stress echocardiography (SE) has been widely used to help clinicians diagnose ischemic heart disease...
Texas Heart Institute, ischemic heart failure, adult stem cell therapy, CONCERT-HF clinical trial
News | Stem Cell Therapies| February 03, 2017
Physicians and researchers at Texas Heart Institute are recruiting patients who suffer from heart failure to...
Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication
Technology | Contrast Media| February 02, 2017
Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity...
Overlay Init